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>48cc group was 90% vs 46% (chi square p =.001). ROC curve 
analysis of our oropharyngeal subgroup revealed similar 
results with a cut off of 48cc with AUC of 0.802 (0.677-0.927) 
and sensitivity / specificity of 86%/70%.The RR for the <48cc 
and >48cc group was 88% vs 40% (chi square p =.001). The 
likelihood of not responding increased by 1.8%% for 1cc 
increase in TTV for the entire cohort and by 2.4% for our 
oropharyngeal subgroup. 
 
 
 
 
Conclusion: Our study shows that the TTV is a significant and 
independent prognostic factor in patients with locally 
advanced head and neck cancer in terms of predicting local 
control. Implications for existing management paradigms 
include, stratification according to TTV in future randomized 
trials and consideration of altered fractionation and/or dose 
escalation to the primary disease for patients with TTV>48cc.  
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Purpose or Objective: To evaluate the prognostic value of 
18F-FDG PET-CT performed prior to (prePET) and during the 
third week (iPET) of radiation therapy (RT) in patients with 
newly diagnosed nasopharyngeal carcinoma (NPC). 
 
Material and Methods: Thirty patients with newly diagnosed 
NPC treated with radical RT and Cisplatin-based 
chemotherapy underwent prePET and iPET. The median 
follow up was 26 months (range 8-66.9). AJCC staging 
included 12 patients in stage II, 8 in stage III and 10 in stage 
IV. The maximum standardised-uptake-value (SUVmax), 
metabolic-tumour-volume (MTV) and total-lesional-glycolysis 
(TLG) of primary tumour (PT), the index-node (IN) (defined as 
lymph node with highest TLG), total lymph nodes (TN) and 
combined primary tumour and nodal (PTN), and their % 
reductions in iPET were analysed, and results were correlated 
with 2-year loco-recurrence-free-survival (LRFS), regional-
failure-free-survival (RFFS), distant-metastatic-failure-free-
survival (DMFFS), disease-free-survival (DFS), and overall-
survival (OS), using Kaplan-Meier (KM) analysis. Optimal-
cutoffs (OC) were derived from Receiver-Operating-
Characteristic curves for the best combined sensitivity and 
specificity. 
 
Results: For LRFS, the only statistically significant predictor 
was reduction in primary tumour MTV by >50% in iPET (95.2% 
vs 75.0%, p=0.024). For other treatment outcomes, only 
nodal or combined PTN predicted treatment outcomes. The 
IN SUVmax (pre-PET OC=10.45g/mL and iPET OC=8.15g/mL) 
and TLG (pre-PET OC=90g and iPET OC=33.4g) provide the 
overall best predictor of outcome, with significant 
associations with RFFS (iPET only), DMFFS (prePET), DFS 
(prePET and iPET) and OS (prePET): For RFFS, iPET IN 
SUVmax and TLG were best predictors: the 2-year KM 
survivals were 100% vs. 50%, p<0.001 and 100% vs. 44%, 
p=0.032 respectively. For DMFFS, prePET IN SUVmax and TLG 
were best predictors: 100% vs. 51.9%, p=0.004 and 100% vs. 
47.6%, p=0.002. For DFS, prePET IN TLG and iPET IN SUVmax 
were best predictors: 87.5% vs. 33%, p=0.045 and 78.7% vs. 
20%, p=0.01. For OS, prePET IN TLG and iPET IN TLG were 
best predictors: 100% vs 72.7%, p=0.048 and 91.7% vs 68.6%, 
p=0.05. The IN metabolic parameters demonstrated stronger 
correlation with outcome than PT or PTN, and equivalent 
correlation to the TN except IN was better in predicting OS. 
 
Conclusion: The metabolic parameters of prePET and iPET 
can provide complementary prognostic biomarkers of patient 
outcomes, These parameters may have a role in adaptive 
therapy for NPC, and identifying the best treatment strategy 
for precision individualised chemo-radiotherapy 
combinations. We have demonstrated IN to be a useful novel 
imaging biomarker for predicting all treatment outcomes, 
and offers additional potential advantage of ease of 
generation and reproducibility compared to TN or PTN. 
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Purpose or Objective: Statistical image features from 
computed tomography (CT) and positron emission 
tomography (PET) scans are being investigated for the 
potential prognostic value in predicting outcome for various 
clinical indications. Here, we analyze primary tumor image 
features from pretreatment FDG-PET and the relation to 
clinical outcomes in patients treated with definitive radiation 
therapy (RT) for laryngeal cancer. 
 
Material and Methods: We identified 83 consecutive patients 
with laryngeal squamous cell carcinoma treated with 
definitive RT with available pretreatment PET/CT scans at 
our institution. Clinical variables related to disease and 
patient characteristics, treatment information, and clinical 
outcomes data were collected for each patient. Pretreatment 
PET/CT scans were used for image feature analysis of the 
primary tumor volume for each patient. Multiple statistical 
image features were computed, along with several measures 
related to the standardized uptake value (SUV). Redundant 
image features were excluded based on a strong correlation 
with parameters commonly reported as important such as 
metabolic tumor volume (MTV) and maximum SUV value 
(SUVmax). A LASSO procedure was applied to select 
appropriate variables to include in Cox proportional hazard 
models for local control (LC) progression-free survival (PFS) 
and overall survival (OS). The concordance index or “C-
index” was computed to evaluate the discriminative ability of 
each model, both on the training data set (apparent C-index) 
and using bootstrap cross-validation (bCV). Correction for 
